tiprankstipranks
Trending News
More News >
MRT Inc. (JP:6034)
:6034
Japanese Market

MRT Inc. (6034) AI Stock Analysis

Compare
0 Followers

Top Page

JP:6034

MRT Inc.

(6034)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
¥624.00
▼(-2.65% Downside)
The overall stock score of 45 reflects MRT Inc.'s mixed financial performance, with strong revenue growth and cash flow improvements but significant profitability challenges. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Cash Flow Management
Strong cash flow management enhances financial flexibility, enabling strategic investments and operational stability.
Low Leverage
Low leverage reduces financial risk and interest obligations, providing a stable foundation for future growth initiatives.
Negative Factors
Profitability Challenges
Ongoing profitability issues may hinder reinvestment capabilities and affect long-term financial health.
Negative Return on Equity
Negative ROE indicates inefficient use of equity capital, potentially impacting investor confidence and future capital raising.
Volatile Cash Flow
Cash flow volatility can lead to uncertainty in funding operations and investments, affecting long-term strategic planning.

MRT Inc. (6034) vs. iShares MSCI Japan ETF (EWJ)

MRT Inc. Business Overview & Revenue Model

Company DescriptionMRT Inc. operates a medical information platform. The company provides temporary and part-time doctor services; doctor's career change support service; Door., an app to connect network of doctors; Door.into, which provides online health counseling, and online medical care; Pocket Doctor, a telemedicine/health consultation app; groupware for medical offices; FASTCALL that consolidates the functions required for hospital crisis management system as safety confirmation service for medical institution; and Good Doctors, which provides owned media sent by doctors. It also offers nurse and pharmacist recruitment service; human resources introduction service for clinical laboratory engineers, radiologists, and dialysis nurses, as well as for new business openings and succession projects; and recruitment information service for exclusive industrial physicians and contract industrial physicians. In addition, the company engages in employment agency business, opening of business, business succession support business, and PR business, and career support business. Further, it offers services for supporting the operation of medical institutions, such as fund management, utilizing medical fee factoring, payroll calculation for doctors' part-time jobs, and payroll transfer agency services. Additionally, the company sells human umbilical cord-derived stem cell culture supernatant; and provides babysitter services, tax accountant referral service, credit card payment agency service, questionnaire survey request for pharmaceuticals, etc., as well as media coverage cooperation, lecture request, event rescue, etc. It also publishes books on illness and treatment; and offers health maintenance service and member comprehensive compensation systems. The company was formerly known as Medical Research and Technology Co., Ltd and changed its name to MRT Inc. in September 2014. MRT Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyMRT Inc. generates revenue through multiple streams, primarily by selling its advanced manufacturing equipment and related services to businesses in various sectors. Key revenue streams include direct sales of machinery, maintenance and support contracts, and consulting services that assist clients in optimizing their manufacturing processes. Additionally, MRT Inc. benefits from strategic partnerships with other technology firms and suppliers, allowing it to enhance its product offerings and expand its market reach. The company also invests in research and development to innovate new products that meet evolving industry needs, contributing to sustained revenue growth.

MRT Inc. Financial Statement Overview

Summary
MRT Inc. is facing financial difficulties, with declining revenue and profitability impacting its income statement. The balance sheet shows a stable capital structure, but the negative return on equity and declining cash flow metrics suggest challenges in sustaining operations.
Income Statement
45
Neutral
MRT Inc. shows a concerning decline in revenue and profitability over the recent periods. The TTM data indicates a negative net profit margin of -8.26%, and EBIT margin of -4.15%, reflecting operational challenges. Despite a slight revenue growth of 1.11% in the TTM, the company has faced significant revenue declines in prior years, impacting overall performance.
Balance Sheet
55
Neutral
The balance sheet reflects a moderate debt-to-equity ratio of 0.16 in the TTM, indicating manageable leverage. However, the return on equity is negative at -7.77%, highlighting profitability issues. The equity ratio remains stable, suggesting a solid capital structure despite recent financial challenges.
Cash Flow
60
Neutral
Cash flow analysis reveals a significant decline in free cash flow growth at -56.11% in the TTM, raising concerns about cash generation capabilities. The operating cash flow to net income ratio is 0.58, indicating some operational cash flow support, but overall cash flow performance has weakened.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.28B4.17B5.41B8.74B4.47B2.56B
Gross Profit2.72B2.74B3.27B5.60B3.55B1.76B
EBITDA308.35M139.00M1.10B3.16B1.45B420.18M
Net Income-168.75M-309.16M517.00M2.16B774.49M131.81M
Balance Sheet
Total Assets6.32B6.75B6.47B8.16B4.98B3.31B
Cash, Cash Equivalents and Short-Term Investments1.83B2.62B3.78B4.90B1.03B1.59B
Total Debt598.18M1.05B641.00M875.86M1.04B1.11B
Total Liabilities1.80B2.12B1.76B3.67B2.69B1.75B
Stockholders Equity4.41B4.52B4.58B4.39B2.22B1.52B
Cash Flow
Free Cash Flow431.78M462.00M-208.00M4.43B-405.64M183.97M
Operating Cash Flow445.19M503.04M-193.00M4.51B-298.89M294.97M
Investing Cash Flow-2.32B-1.84B-243.61M-431.11M-206.51M-64.61M
Financing Cash Flow-197.96M161.77M-669.19M-203.98M-67.49M-397.41M

MRT Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price641.00
Price Trends
50DMA
651.20
Negative
100DMA
678.29
Negative
200DMA
692.50
Negative
Market Momentum
MACD
-6.83
Positive
RSI
47.04
Neutral
STOCH
49.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6034, the sentiment is Neutral. The current price of 641 is below the 20-day moving average (MA) of 647.40, below the 50-day MA of 651.20, and below the 200-day MA of 692.50, indicating a bearish trend. The MACD of -6.83 indicates Positive momentum. The RSI at 47.04 is Neutral, neither overbought nor oversold. The STOCH value of 49.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:6034.

MRT Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥3.44B13.781.88%6.68%2.86%
67
Neutral
¥8.23B12.098.77%32.95%45.22%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
¥2.33B-3.3516.19%-4.42%
45
Neutral
¥3.58B-20.501.51%-13.66%
43
Neutral
¥65.75B-152.460.39%6.17%-8918.66%
40
Underperform
¥6.39B-2.37-4.07%-88.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6034
MRT Inc.
641.00
-29.00
-4.33%
JP:3628
Data Horizon Co., Ltd.
506.00
73.00
16.86%
JP:3671
Softmax Co., Ltd. (Japan)
342.00
140.14
69.42%
JP:3902
Medical Data Vision Co.Ltd.
1,686.00
1,322.35
363.63%
JP:4438
Welby Inc.
282.00
-51.00
-15.32%
JP:6545
internet infinity INC.
640.00
188.96
41.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 11, 2025